Meeting
2018 Gastrointestinal Cancers Symposium
Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane.
Authors
Tamotsu Sagawa
Hokkaido Cancer Center, Sapporo, Japan
Tamotsu Sagawa , Hironaga Satake , Koshi Fujikawa , Yukimasa Hatachi , Hisateru Yasui , Masahito Kotaka , Takeshi Kato , Akihito Tsuji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000018606
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 155)
DOI
10.1200/JCO.2018.36.4_suppl.155
Abstract #
155
Poster Bd #
K15
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – the RAMIRIS Study.
First Author: Sylvie Lorenzen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter retrospective study of ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma patients previously treated with platinum-based chemotherapy: RAM-NEC study (WJOG13420G).
First Author: Hidekazu Hirano
First Author: Sylvie Lorenzen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz